BioCentury
ARTICLE | Clinical News

Diazoxide choline controlled release: Phase I data

April 6, 2015 7:00 AM UTC

The open-label first part of the 2-part, U.S. Phase I PC025 trial in 13 obese Prader-Willi patients ages 10-22 showed that oral DCCR for 10 weeks significantly reduced body fat by 4.2% (p=0.003), redu...